Clal Finance downgrades Teva on Copaxone concerns – Globes
|
Clal Finance downgrades Teva on Copaxone concerns
Globes Clal Finance Ltd. has downgraded its recommendation for Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA; TASE: TEVA) to "Market perform" with no target price. Analyst Yonatan Kreizman says that if Biogen Inc. (Nasdaq: BIIB) publishes positive results … |
